Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $29.00 price target on the stock.
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer [Yahoo! Finance]
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.